Background
Lymphocyte Activation Gene 3 (LAG3) or CD223, a cell surface molecule, is expressed on multiple cell types including CD4+ and CD8+ T cells, and Tregs, and is required for optimal T cell regulation and homeostasis. Persistent antigen-stimulation in cancer or chronic infection leads to chronic LAG3 expression, promoting T cell exhaustion. LAG3 is an immune checkpoint receptor and as such is the target of various drug development programs to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.
Product Details
| Source | HEK293 Cells |
| Accession # | P18627 |
| Sequence | Human LAG3 (Met1-Leu450) + 6xHis tag (N-terminus to C-terminus) |
| Purification | Affinity purified and size-HPLC |
| Purity | >95%, by SDS-PAGE. |
| Activity | Measured by its ability to bind Anti-LAG3(BMS)-IgG4 Antibody (Relatlimab), the EC50 is 6-30 ng/mL. |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in sterile PBS. |
| Predicted Molecular Weight | 47 kDa |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |
References
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990, 171(5):1393-405.
Sigrid Hannier, Muriel Tournier, Georges Bismuth, Frédéric Triebel; CD3/TCR Complex-Associated Lymphocyte Activation Gene-3 Molecules Inhibit CD3/TCR Signaling. J Immunol. 1998, 161 (8): 4058–4065.